Clinical antifungal efficacy trials in invasive aspergillosis: Consensus standards for trial design and room for improvement

References

• Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408–415
   PubMed Web of Science ®Google Scholar
• Cornely OA, Maertens J, Bresnik M, Herbrecht R. Liposomal amphotericin B (L-AMB) as initial therapy for invasive filamentous fungal infections (IFFI): A randomized, prospective trial of a high loading regimen vs. standard dosing (AmBiLoad Trial). Blood 2005; 106: Abstract 3222.
   PubMed Web of Science ®Google Scholar
• Yeghen T, Kibbler CC, Prentice HG, et al. Management of invasive pulmonary aspergillosis in hematology patients: a review of 87 consecutive cases at a single institution. Clin Infect Dis 2000; 31: 859–868
   PubMed Web of Science ®Google Scholar
• Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7–14
   PubMed Web of Science ®Google Scholar
• Greene RE, Schlamm HT, Stark P, , et al. Radiological findings in acute invasive pulmonary aspergillosis: Utility and reliability of halo sign and air-crescent sign for diagnosis and treatment of IPA in high-risk patients. Proceedings of the 13th European Conference on Clinical Microbiology and Infectious Diseases, Glasgow, Scottland, 10–13 May, 2003.
   Google Scholar
• Denning DW, Ribaud P, Milpied N, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002; 34: 563–571
   PubMed Web of Science ®Google Scholar
• Patterson TF, Kirkpatrick WR, White M, et al. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. Medicine (Baltimore) 2000; 79: 250–260
   PubMed Web of Science ®Google Scholar
• Bohme A, Ruhnke M, Buchheidt D, et al. Treatment of fungal infections in hematology and oncology – guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2003; 82(Suppl. 2)S133–S140
   Google Scholar
• Denning DW, Kibbler CC, Barnes RA. British Society for Medical Mycology proposed standards of care for patients with invasive fungal infections. Lancet Infect Dis 2003; 3: 230–240
   PubMed Web of Science ®Google Scholar
• Gavalda J, Ruiz I. Guidelines for the treatment of invasive fungal infection. Invasive fungal infection by Candida spp. Invasive Fungal Infection Study Group (MICOMED) and Infection in Transplantation Study Group (GESITRA) of the Spanish Society for Infectious Diseases and Clinical Microbiology (SEIMC). Enferm Infecc Microbiol Clin 2003; 21: 498–508
   PubMed Web of Science ®Google Scholar
• SFAR, SPILF, SRLF. Management of invasive candidiasis and aspergillosis in adults. Rev Pneumol Clin 2004; 60: 289–293.
   PubMedGoogle Scholar
• Slavin MA, Szer J, Grigg AP, et al. Guidelines for the use of antifungal agents in the treatment of invasive Candida and mould infections. Intern Med J 2004; 34: 192–200
   PubMed Web of Science ®Google Scholar
• Kuhlman JE, Fishman EK, Burch PA, et al. Invasive pulmonary aspergillosis in acute leukemia. The contribution of CT to early diagnosis and aggressive management. Chest 1987; 92: 95–99
   PubMed Web of Science ®Google Scholar
• Patterson TF, Boucher HW, Herbrecht R, et al. Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome. Clin Infect Dis 2005; 41: 1448–1452
   PubMed Web of Science ®Google Scholar
• Herbrecht R, Johnson EM, Barette M, et al. Longitudinal assessment of galactomannan antigenemia and relationship with outcome in invasive aspergillosis. Advances Against Aspergillosis, San Francisco, 9–11 September, 2004. Med Mycol, 43, S1, Poster Abstract, 61.
   Google Scholar
• Herbrecht R, Letscher-Bru V, Oprea C, et al. Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients. J Clin Oncol 2002; 20: 1898–1906
   PubMed Web of Science ®Google Scholar
• Maertens J, Verhaegen J, Lagrou K, Van Eldere J, Boogaerts M. Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood 2001; 97: 1604–1610
   PubMed Web of Science ®Google Scholar
• Maertens J, Theunissen K, Verbeken E, et al. Prospective clinical evaluation of lower cut-offs for galactomannan detection in adult neutropenic cancer patients and haematological stem cell transplant recipients. Br J Haematol 2004; 126: 852–860
   PubMed Web of Science ®Google Scholar
• Marr KA, Balajee SA, McLaughlin L, et al. Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. J Infect Dis 2004; 190: 641–649
   PubMed Web of Science ®Google Scholar
• Maertens J, Glasmacher A, Herbrecht R, , et al Multicenter, noncomparative study of caspofungin combined with other antifungals in adults with invasive aspergillosis refractory or intolerant to prior therapy: final results. Proceeding of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy; Washington, DC, 16–19 December, 2005: Abstract M-954, p. 420.
   Google Scholar
• Ribaud P, Chastang C, Latge JP, et al. Survival and prognostic factors of invasive aspergillosis after allogeneic bone marrow transplantation. Clin Infect Dis 1999; 28: 322–330
   PubMed Web of Science ®Google Scholar
• Cordonnier C, Ribaud P, Herbrecht R, et al. Prognostic factors for death due to invasive aspergillosis after hematopoietic stem cell transplantation: a 1-year retrospective study of consecutive patients at French transplantation centers. Clin Infect Dis 2006; 42: 955–963
   PubMed Web of Science ®Google Scholar
• Fukuda T, Boeckh M, Carter RA, et al. Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood 2003; 102: 827–833
   PubMed Web of Science ®Google Scholar
• Cornely OA, Maertens J, Bresnik M, Herbrecht, R. Prognosis factors. Advances Against Aspergillosis, Athens, 2006 Med Mycol, Supplement (in preparation).
   Google Scholar
• Kullberg BJ, Sobel JD, Ruhnke M, et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 2005; 366: 1435–1442
   PubMed Web of Science ®Google Scholar
• Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347: 2020–2029
   PubMed Web of Science ®Google Scholar
• van Burik JA, Ratanatharathorn V, Stepan DE, et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004; 39: 1407–1416
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999; 340: 764–771
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Pappas P, Winston DJ, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002; 346: 225–234
   PubMed Web of Science ®Google Scholar